EP2014653A1 — Novel dicarboxylic acid derivatives as S1P1 receptor agonists
Assigned to Bioprojet SC · Expires 2009-01-14 · 17y expired
What this patent protects
The present invention provides a novel class of 3-phenyl or 5-phenyl-1,2,4-oxadiazole based dicarboxylic acid derivatives useful as S1P1 receptor agonists, their process of preparation and their therapeutic use.
USPTO Abstract
The present invention provides a novel class of 3-phenyl or 5-phenyl-1,2,4-oxadiazole based dicarboxylic acid derivatives useful as S1P1 receptor agonists, their process of preparation and their therapeutic use.
Drugs covered by this patent
- Velsipity (Etrasimod Arginine) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.